Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma

Table 4

Prognostic factors for overall survival and progression-free survival determined by univariate and multivariate analyses.

Variables	Overall survival				Progression-free survival
	Univariate		Multivariate		Univariate		Multivariate
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
AFP ≤400/>400	0.166 (0.046, 0.604)	0.006	0.234 (0.063, 0.869)	0.030	0.368 (0.163, 0.832)	0.016	0.326 (0.107, 0.994)	0.049
Age (years) ≤60/>60	0.524 (0.178, 1.540)	0.240			1.880 (0.847, 4.171)	0.121	2.632 (0.751, 9.223)	0.130
ALT (U/L) ≤35/>35	0.648 (0.233, 1.807)	0.407			0.373 (0.157, 0.890)	0.026	0.390 (0.152, 1.002)	0.051
AST (U/L) ≤40/>40	0.658 (0.224, 1.935)	0.447			0.804 (0.362, 1.784)	0.591
BCLC stage A + B/C	1.055 (0.294, 3.788)	0.935			0.863 (0.342, 2.174)	0.754
Child–Pugh stage A/B	2.334 (0.520, 10.47)	0.268			1.009 (0.400, 2.542)	0.985
DEB-TACE procedures ≤2/>2	1.098 (0.395, 3.046)	0.858			0.865 (0.405, 1.849)	0.709
Diabetes, no/yes	0.755 (0.169, 3.372)	0.713			0.841 (0.286, 2.467)	0.752
Diameter (cm) ≤5/>5	0.264 (0.057, 1.228)	0.090	0.561 (0.084,3.762)	0.551	0.330 (0.119, 0.912)	0.033	1.190 (0.277, 5.117)	0.816
Extrahepatic metastasis, no/yes	0.825 (0.289, 2.352)	0.825			0.477 (0.217, 1.051)	0.066	0.745 (0.253, 2.194)	0.594
Hepatitis B, no/yes	0.783 (0.275, 2.229)	0.647			0.589 (0.253, 1.374)	0.221
Hypertension, no/yes	0.581 (0.181, 1.864)	0.362			0.623 (0.240, 1.614)	0.33
Immunotherapy, no/yes	0.780 (0.266, 2.289)	0.651			0.810 (0.352, 1.865)	0.621
Other treatments, no/yes	2.257 (0.615, 8.282)	0.220			2.481 (0.970, 6.343)	0.058	2.334 (0.655, 8.319)	0.191
PLT×10^9/L	1.002 (0.997, 1.007)	0.350			1.004 (1.000, 1.008)	0.033	0.999 (0.995, 1.004)	0.796
Portal vein invasion, no/yes	0.351 (0.126, 0.980)	0.046	0.283 (0.076, 1.046)	0.058	0.561 (0.235, 1.337)	0.192	0.772 (0.201, 2.972)	0.707
PT (s) ≤14/>14	1.528 (0.430, 5.427)	0.512			2.426 (0.832, 7.071)	0.104	3.951 (0.946, 16.505)	0.060
Sex, female/male	0.177 (0.023, 1.351)	0.095	0.509 (0.059, 4.399)	0.539	0.566 (0.213, 1.504)	0.253
Targeted therapy, no/yes	0.434 (0.122, 1.539)	0.196	0.761 (0.190, 3.048)	0.699	0.556 (0.242, 1.278)	0.167	0.860 (0.332, 2.229)	0.756
Tumor number, single/multiple	0.379 (0.126, 1.139)	0.084	0.311 (0.073, 1.327)	0.115	0.448 (0.189, 1.061)	0.068	0.252 (0.064, 1.003)	0.050

ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha-fetoprotein; PLT, platelets; BCLC, Barcelona Clinic Liver Cancer strategy; DEB-TACE, drug-eluting transarterial chemoembolization; PLT, platelet; PT, prothrombin time.